Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control  by Kohan, Donald E. et al.
OPEN
see commentary on page 745
Long-term study of patients with type 2 diabetes and
moderate renal impairment shows that dapagliflozin
reduces weight and blood pressure but does not
improve glycemic control
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In patients with diabetes, glycemic improvement by sodium-
glucose cotransporter-2 inhibition depends on the kidney’s
ability to filter glucose. Dapagliflozin, a sodium-glucose
cotransporter-2 inhibitor, reduces hyperglycemia in patients
with diabetes and normal or mildly impaired renal function.
In this randomized, double-blind, placebo-controlled study
we assessed daily treatment with dapagliflozin in 252
patients with inadequately controlled type 2 diabetes and
moderate renal impairment. The primary endpoint, the mean
change in HbA1c, was not statistically different from placebo
after 24 weeks ( 0.41% and  0.44% for 5- and 10-mg
doses, respectively, and  0.32% for placebo). The mean
weight change from baseline was  1.54 and  1.89kg for
the 5- and 10-mg doses, respectively, and þ 0.21kg for
placebo. The mean systolic and diastolic blood pressure
decreased in the dapagliflozin groups compared to placebo.
Through 104 weeks, 13 patients receiving dapagliflozin and
no patients receiving placebo experienced bone fracture. At
1 week, the mean serum creatinine increased with
dapagliflozin 5mg (þ 0.13mg/dl) and 10mg (þ 0.18mg/dl)
and did not change further after 104 weeks. Mean serum
electrolytes did not change in any group, and there were
fewer episodes of hyperkalemia with dapagliflozin than
placebo. Thus, in patients with moderate renal impairment,
dapagliflozin did not improve glycemic control, but reduced
weight and blood pressure.
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Current medications for treating type 2 diabetes mellitus
(T2DM) target the pancreas, liver, intestines, muscle, or adi-
pose tissue and act by increasing insulin secretion or action,
or by improving insulin sensitivity.1 The sodium-glucose
cotransporter-2 (SGLT2), located in the renal proximal
tubule, reabsorbs the majority of filtered glucose.2,3 Inhi-
bition of renal glucose reabsorption via inhibition of SGLT2,
an insulin-independent process, represents a novel approach
to treating T2DM.
Several clinical trials with dapagliflozin, a potent and
selective SGLT2 inhibitor, showed that it reduces hyperglycemia
and improves glycemic control in patients with T2DM.
These trials examined dapagliflozin as monotherapy4 or in
combination with metformin,5 sulfonylureas,6,7 thiazolidine-
diones,8 or insulin.9,10 Treatment with dapagliflozin induces
glucosuria, resulting in caloric elimination and weight loss.4–11
A decrease in blood pressure has also been observed4–11 and
may occur as a consequence of osmotic diuresis and weight loss.
The mechanism of dapagliflozin depends on filtration of
glucose at the glomerulus. Thus, with reduced renal function,
dapagliflozin is expected to be less efficacious. Previous
studies have shown efficacy of dapagliflozin in populations
consisting primarily of patients with normal renal function
or mild renal impairment. This study examines the efficacy
and safety of dapagliflozin in patients with T2DM and mode-
rate renal impairment.
RESULTS
Disposition and demographics
Of the 631 enrolled patients, 252 were randomized
(Figure 1). A total of 203 patients completed the first
24 weeks (short-term period), 202 entered the additional
28-week period (long-term period) with 182 completing it,
and 171 entered the second year (extension period), with 139
completing it (Figure 1). The short-term completion rate
was lower for placebo (73.8%) than for dapagliflozin 5-mg
(86.7%) and 10-mg (81.2%) groups, the main difference
being higher rate of discontinuations for adverse events for
placebo during the first 24 weeks than for dapagliflozin.
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Groups generally appeared to be balanced with respect to key
demographic and baseline characteristics (Table 1).
Efficacy
In this moderate renal impairment population, the primary
end point, mean change in hemoglobin A1c (HbA1c; % (s.e))
excluding data after glycemic rescue, was not statistically
different from placebo at week 24 ( 0.32 (0.17),  0.41
(0.17), and  0.44 (0.17) for placebo, 5 and 10-mg
dapagliflozin, respectively, and P¼ 0.561 and P¼ 0.435 for
dapagliflozin 5 and 10mg vs. placebo, respectively; Table 2).
Changes in HbA1c at 52 and at 104 weeks are shown in
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Figure 1 | Trial profile through 104 weeks. A total of five patients left the trial because they ‘no longer met study criteria.’ For the three
patients in the placebo group, (1) the patient had insulin regimen altered, which is against the protocol guidance, (2) the patient met
discontinuation criteria for sustained elevated serum creatinine, and (3) the patient was inappropriately randomized with a high screening
potassium and removed a few days after starting treatment. The patient in the 5-mg group had myasthenia gravis, was administered
prednisone for treatment and was asked to be discontinued by the medical monitor. The patient in the 10-mg group was discontinued owing
to serum creatinine greater than two times the baseline at day 78.
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Table 3. Fasting plasma glucose (FPG) showed larger mean
reductions for dapagliflozin 5 and 10mg compared with
placebo at 24 weeks (Table 2) and over 104 weeks (Table 3).
Similar results for HbA1c and FPG were obtained in analyses
that include data after glycemic rescue.
There was an increase in the 24-h urine glucose:creatinine
ratio with dapagliflozin compared with placebo (Table 3;
Figure 2). The dapagliflozin groups experienced mean weight
loss, whereas there was an increase in the placebo group
(Figure 2 and Table 3).
Post-hoc analysis by baseline chronic kidney disease (CKD)
stage (Table 4) showed a larger reduction in adjusted mean
change in HbA1c and FPG from baseline to week 24 for
dapagliflozin vs. placebo for stage 3A CKD (estimated
glomerular filtration rate (eGFR) X45 and o60ml/min
per 1.73m2) than for stage 3B CKD (eGFR X30 and
o45ml/min per 1.73m2). The placebo-corrected mean
reduction from baseline in HbA1c at week 24 for dapagli-
flozin treatment groups in patients in stage 3A ranges
between 0.33 and 0.37, whereas there is no change observed
in patients in stage 3B. No difference was observed for change
in body weight at week 24 between stages 3A and 3B
(Table 4).
Safety
The proportions of patients experiencing an adverse event
were similar for dapagliflozin and placebo (Table 5). More
patients in the placebo group had adverse events leading to
discontinuation (Table 5) than in dapagliflozin groups. Ten
deaths were reported during the 104 weeks of treatment: 5 in
placebo (1—traumatic brain injury, 2—acute myocardial
infarction, 1—acute cardiac failure, myocardial infarction,
and renal failure, and 1—general physical health deteriora-
tion), 2 in dapagliflozin 5mg (both with myocardial
infarction and cardiac arrest), and 3 in dapagliflozin 10mg
(1 each—myocardial infarction, cardiac failure, and sepsis).
The proportions of patients with serious adverse events
through the 104-week treatment period were similar for
dapagliflozin and placebo. A higher incidence of genital
infections was reported with dapagliflozin than placebo, and
a similar incidence of patients experienced urinary tract
infections with dapagliflozin and placebo (Table 5).
Through 104 weeks, 13 (7.7%) patients experienced
fracture in the dapagliflozin groups (5 at 5mg and 8 at
10mg) vs. 0 on placebo (Table 5). All fractures occurred after
trauma and were mostly of low impact. Two of 13 fractures
were assessed as serious adverse events (1 hip and 1 elbow,
both with dapagliflozin 10mg). None of these events led to
discontinuation of study medication. Seven of 13 patients
who sustained fracture had a history of diabetic neuropathy or
exhibited orthostatic hypotension. Of the 13 patients report-
ing fracture, 5 had stage 3A CKD and 8 had stage 3B CKD.
Events of renal impairment or renal failure were
uncommon during the 104-week period (Table 5). Reports
of volume depletion events were more frequent in the
dapagliflozin groups than in the placebo group (Table 5). Six
Table 1 |Demographics and baseline characteristics
Placebo
Dapagliflozin
5mg
Dapagliflozin
10mg
n 84 83 85
Age (years) 67±8.6 66±8.9 68±7.7
Men 53 (63.1) 55 (66.3) 56 (65.9)
Women 31 (36.9) 28 (33.7) 29 (34.1)
Geographic region
North America 41 (48.8) 51 (61.4) 48 (56.5)
Latin America 23 (27.4) 15 (18.1) 17 (20.0)
Europe 11 (13.1) 9 (10.8) 9 (10.6)
Asia/Pacific 9 (10.7) 8 (9.6) 11 (12.9)
Race
White 69 (82.1) 65 (78.3) 77 (90.6)
African American 1 (1.2) 7 (8.4) 4 (4.7)
Asian 6 (7.1) 4 (4.8) 3 (3.5)
Other 8 (9.5) 7 (8.4) 1 (1.2)
HbA1c (%) 8.53±1.28 8.30±1.04 8.22±0.98
FPG (mg/dl) 149±48 161±56 164±66
Weight (kg) 89.6±20.0 95.2±20.9 93.2±17.3
BMI, X30 kg/m2 50 (59.5) 59 (71.1) 54 (63.5)
Duration of diabetes (years) 15.7±9.5 16.9±9.0 18.2±10.1
Pre-enrollment antihyperglycemic therapy
Insulin based 55 (65.5) 54 (65.1) 55 (64.7)
Sulfonylurea based 21 (25.0) 21 (25.3) 21 (24.7)
Thiazolidinedione based 1 (1.2) 1 (1.2) 2 (2.4)
Other 7 (8.3) 7 (8.4) 7 (8.2)
Chronic kidney disease stage: eGFR (ml/min per 1.73m2)
Stage 4: o30 4 (4.8) 4 (4.8) 2 (2.4)
Stage 3B: X30 and o45 34 (40.5) 41 (49.4) 47 (55.3)
Stage 3A: X45 and o60 41 (48.8) 35 (42.2) 33 (38.8)
Stage 2: X60 5 (6.0) 3 (3.6) 3 (3.5)
Urinary albumin:creatinine ratioa
(mg/g)
67 (20,
367)
79 (13, 539) 73 (9, 352)
Urinary protein:creatinine ratioa
(mg/mg)
0.75±1.77 0.72±1.22 0.63±1.12
Patients with diabetic nephropa-
thy
60 (71.4) 61 (73.5) 58 (68.2)
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate;
FPG, fasting plasma glucose; HbA1c, hemoglobin A1c.
Data are means±s.d. or n (%).
aMeasured by spot urine samples and urinary albumin:creatinine ratio is median
(25, 75 percentiles).
Table 2 | Efficacy at 24 weeksa
Placebo
(n¼ 84)
Dapagliflozin
5mg (n¼ 83)
Dapagliflozin
10mg
(n¼ 85)
HbA1c (%)
nb 82 83 82
Baseline mean (s.d.) 8.53 (1.29) 8.30 (1.04) 8.22 (0.97)
Mean change from baseline
(s.e.)
 0.32 (0.17)  0.41 (0.17)  0.44 (0.17)
Difference from placebo (s.e.)  0.08 (0.14)  0.11 (0.15)
P-value vs. placeboc 0.561 0.435
FPG (mg/dl)
nb 83 83 84
Baseline mean (s.d.) 150.2 (48.2) 161.4 (55.9) 164.8 (66.8)
Mean change from baseline
(s.e.)
8.4 (9.62)  5.2 (9.55)  0.6 (9.52)
Difference from placebo (s.e.)  13.6 (8.14)  9.0 (8.14)
Abbreviations: ANCOVA, analysis of covariance; FPG, fasting plasma glucose; HbA1c,
hemoglobin A1c; LOCF, last observation carried forward.
aUsing ANCOVA with LOCF excluding data after rescue.
bn is the number of randomized patients with non-missing baseline and week 24
(LOCF) values.
cPrimary end point (HbA1c) was tested at alpha¼ 0.027 applying Dunnett’s
adjustment, and secondary end point (FPG) was tested following a sequential
testing procedure at alpha¼ 0.05.
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patients (two on dapagliflozin 10mg and four on placebo)
experienced major episodes of hypoglycemia through the 104
weeks (Table 5).
Blood pressure
At week 1, there were mean reductions from baseline in
seated systolic and diastolic blood pressure ( 6.83 and
 2.53mmHg, respectively) for dapagliflozin 10mg. The
magnitude of the mean reductions was generally stable for
the first 52 weeks for this treatment group ( 6.73 and
 2.91mmHg, respectively). These reductions lessened
somewhat after week 52 (Table 6). Although the proportion
of patients with measured orthostatic hypotension at any
assessment time during the 104 weeks was higher for the
dapagliflozin groups (7.8% to 15.6%) than for the placebo
group (2.9% to 10.5%), this difference appears to reflect a
higher rate of orthostatic hypotension seen in dapagliflozin at
baseline (14.5% and 14.1% for the dapagliflozin 5- and 10-
mg groups, respectively, vs. 7.1% for placebo).
Laboratory parameters with abnormalities
A mean increase from baseline in serum creatinine was
observed at week 1 in dapagliflozin 5mg (0.13 mg/dl) and
10mg (0.18mg/dl). The magnitude of this mean increase
remained unchanged throughout the remainder of the study
for dapagliflozin (Table 6). A similar pattern was seen for
eGFR and creatinine clearance, with early mean decreases at
week 1 followed by longer-term stability (Table 3 and
Figure 3). Mean changes in eGFR through week 104 did not
appear to differ for CKD stage 3A or stage 3B patients. The
proportion of patients with a marked abnormality in serum
creatinine (defined as a value X2.5 or X1.5mg/dl increase
from baseline) through 104 weeks of treatment was similar
across the treatment groups. Over time, mean urinary
albumin:creatinine and urinary protein:creatinine ratios
fluctuated in all groups. Values of urinary albumin:creatinine
ratio41800mg/g during the 104-week treatment period were
reported in a higher proportion of patients in placebo
(13.3%) than in dapagliflozin 5 or 10mg (10.8% and 9.5%,
respectively). In shift analyses, urinary albumin:creatinine
Table 3 | Change from baseline in efficacy and renal parametersa
Placebo (n¼ 84) Dapagliflozin 5mg (n¼ 83) Dapagliflozin 10mg (n¼ 85)
n Value n Value n Value
HbA1c (%)b
Baseline 84 8.53 (1.28) 83 8.30 (1.04) 83 8.23 (0.98)
Change at week 24 50  0.28 [0.13] 63  0.38 [0.13] 65  0.41 [0.13]
Change at week 52 13  0.06 [0.18] 30  0.34 [0.16] 35  0.34 [0.16]
Change at week 104 4  0.67 [0.41] 8  1.21 [0.38] 10  0.75 [0.22]
FPG (mg/dl)b
Baseline 84 150 (48) 83 161 (56) 84 165 (67)
Change at week 24 50 2.53 [6.86] 60  9.51 [6.35] 65  9.29 [6.24]
Change at week 52 13  8.58 [9.00] 29  14.98 [6.78] 33  16.49 [6.54]
Change at week 104 4  18.25 [36.62] 8  31.00 [13.55] 10  22.10 [8.22]
24-H urinary glucose:creatinine ratio (g/g)c
Baseline 65 7.19 (23.15) 72 3.16 (7.08) 68 5.43 (12.75)
Change at week 6 63  2.20 (23.40) 69 24.39 (18.75) 63 24.78 (16.46)
Change at week 52 34  5.01 (25.07) 40 26.84 (15.37) 38 21.74 (17.47)
Change at week 104 36  4.81 (30.03) 33 26.24 (14.60) 38 21.97 (20.08)
Weight (kg)d
Baseline 84 89.6 (20.1) 83 95.2 (20.9) 85 93.3 (17.3)
Change at week 24 63 0.68 [0.45] 70  1.34 [0.43] 69  1.72 [0.44]
Change at week 52 51 1.10 [0.60] 64  1.17 [0.55] 64  1.75 [0.56]
Change at week 104 42 2.63 [0.79] 41  0.34 [0.75] 51  1.10 [0.74]
eGFR (ml/min per 1.73m2)
Baseline 84 45.6 (10.0) 83 44.2 (8.8) 85 43.9 (10.6)
Change at week 24 62  0.25 [0.92] 70  2.38 [0.84] 69  4.80 [0.82]
Change at week 52 49  2.58 [1.16] 64  2.08 [0.99] 63  4.46 [0.97]
Change at week 104 42  2.38 [1.01] 40  1.71 [1.23] 50  3.50 [1.02]
CrCl (ml/min)
Baseline 84 60.4 (17.3) 83 62.3 (17.3) 85 59.9 (17.8)
Change at week 24 62 0.03 [1.11] 69  4.02 [1.10] 69  7.38 [0.97]
Change at week 52 49  2.56 [1.31] 64  4.15 [1.13] 63  7.27 [1.23]
Change at week 104 42  2.35 [1.27] 40  3.30 [1.69] 50  6.32 [1.22]
Abbreviations: CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c.
aData are mean (s.d.) or mean [s.e.].
bUsed longitudinal repeated-measure analysis excluding data after rescue.
cUsed descriptive statistics including data after rescue.
dUsed longitudinal repeated-measure analysis including data after rescue.
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ratio was characterized as belonging to one of three
prespecified categories: 0 to o30mg/g (normoalbuminuria),
30 to o300mg/g (microalbuminuria), or X300mg/g
(macroalbuminuria), and showed that for dapagliflozin-
treated patients, relative to baseline, 38 patients shifted to a
lower category at week 104 (18 patients from microalbumi-
nuria to normoalbuminuria, 19 from macroalbuminuria to
microalbuminuria, and 1 from macroalbuminuria to nor-
moalbuminuria) compared with 18 patients who shifted to a
higher category (12 patients from normoalbuminuria to
microalbuminuria and 6 from microalbuminuria to macro-
albuminuria). In the placebo group, the number of patients
who shifted to a lower category (nine patients, five from
microalbuminuria to normoalbuminuria and four from
macroalbuminuria to microalbuminuria) was similar to the
number of patients who shifted to a higher category (12
patients, 3 from normoalbuminuria to microalbuminuria and
9 from microalbuminuria to macroalbuminuria). For one
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Figure 2 |Mean change from baseline in HbA1c, urinary glucose:creatinine ratio, and body weight for placebo (circles, solid line),
dapagliflozin 5-mg (squares, dashed line), and dapagliflozin 10-mg (triangles, dotted line) groups, all plus original pre-enrollment
antidiabetic regimen up to 104 weeks. Data are means (95% confidence interval (CI)). Mean change from baseline in HbA1c after adjustment
for baseline value (a), mean change from baseline in urinary glucose:creatinine ratio (g/g) after adjustment for baseline value (b), and mean
change from baseline in body weight after adjustment for baseline value (c). HbA1c and weight obtained from longitudinal repeated-measure
analysis; HbA1c excludes data after rescue; urinary glucose:creatinine ratio and weight include data after rescue. Treatment symbols shifted
horizontally to prevent error bar overlapping. DAPA, dapagliflozin; HbA1c, hemoglobin A1c; PBO, placebo.
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patient each in the dapagliflozin groups and the placebo
group, the shift was not reported, and the remaining patients
did not exhibit a shift from baseline at week 104.
No change from baseline was noted in mean serum
sodium, potassium, bicarbonate, chloride, or calcium with
dapagliflozin or placebo. No evidence of hyponatremia or
hypokalemia was observed. Marked abnormalities of elevated
potassium (X6mEq/l) were more common in the placebo
group (12.0%) than in dapagliflozin 5-mg (4.8%) or 10-mg
groups (4.8%) during the study. More patients experienced
marked abnormalities of hyperphosphatemia (X5.6mg/dl
for patients 17 to 65 years of age or X5.1mg/dl for patients
X66 years of age) on treatment with dapagliflozin 5mg
(15.7%) or 10mg (14.3%) than placebo (8.4%). Patients
receiving dapagliflozin had a larger mean decrease in serum
uric acid than those receiving placebo (Table 6). The mean
concentration of serum parathyroid hormone exceeded the
upper limit of normal at baseline in all treatment groups, and
there were larger mean increases in parathyroid hormone in
dapagliflozin compared with placebo during the cumulative
104-week period (Table 6).
DISCUSSION
Dapagliflozin’s ability to inhibit renal glucose reabsorption
declines with decreasing GFR. Urinary glucose excretion is
about 50% lower in patients with T2DM treated with
dapagliflozin having CKD stage 3, as compared with patients
with normal or mildly impaired renal function.11 Such GFR
dependence is expected given the fall in filtered glucose
load with worsening CKD stage. Consistent with the lower
pharmacodynamic activity, dapagliflozin did not have a
significant impact on glycemic control in patients with more
advanced CKD, although there was a modest decrease in
HbA1c and FPG in patients with a GFR of 45–59 ml/min.
Dapagliflozin showed improvements in weight despite
lacking glycemic efficacy. Patients receiving dapagliflozin had
modest weight loss in contrast to those receiving placebo,
who had small weight gain. The placebo-subtracted weight
changes observed here are similar to other studies in patients
with normal to mildly impaired renal function,4–9 and the
weight loss in this study was similar between patients in CKD
stages 3A and 3B. The apparent incongruity in glycemic and
weight outcomes may be due to a variety of factors. Patients
in this study may have already reached a threshold of
glucosuria, beyond which further weight loss was not
achieved because of compensatory mechanisms to defend
Table 4 | Efficacy by baseline CKD stages 3A and 3B at 24 weeksa
HbA1c (%) FPG (mg/dl) Weight (kg)
n
Difference from
placebo n
Difference from
placebo n
Difference from
placebo
This study
Stage 3B: eGFR X30 and o45 ml/min per 1.73m2
Dapagliflozin 5mg 41 0.05 (0.21) 41  2.66 (12.1) 41  2.1 (0.69)
Dapagliflozin 10mg 45 0.07 (0.21) 46  1.49 (11.8) 47  2.2 (0.68)
Stage 3A: eGFR X45 and o60 ml/min per 1.73m2
Dapagliflozin 5mg 35  0.37 (0.23) 35  24.8 (12.4) 35  1.9 (0.66)
Dapagliflozin 10mg 32  0.33 (0.24) 33  24.4 (12.7) 33  2.3 (0.68)
Abbreviations: ANCOVA, analysis of covariance; CKD, chronic kidney disease; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; LOCF, last observation carried forward.
aData are difference in adjusted mean (s.e.) change from baseline of dapagliflozin vs. placebo (LOCF), excluding data after rescue based on an ANCOVA model with
treatment group and stratum as main effects and baseline value as a covariate.
Table 5 | Adverse and special interest events through
week 104
Placebo
Dapagliflozin
5mg
Dapagliflozin
10mg
n 84 83 85
Adverse event 77 (91.7) 80 (96.4) 77 (90.6)
Related adverse event 39 (46.4) 39 (47.0) 41 (48.2)
Adverse event leading to dis-
continuation
22 (26.2) 16 (19.3) 11 (12.9)
At least one serious adverse
event
26 (31.0) 21 (25.3) 26 (30.6)
Deaths 5 (6.0) 2 (2.4) 3 (3.5)
Adverse events of special interest
Suggestive of urinary tract
infection
12 (14.3) 11 (13.3) 12 (14.1)
Suggestive of genital tract
infection
3 (3.6) 8 (9.6) 7 (8.2)
Renal impairment or failure
(total)
6 (7.1) 2 (2.4) 8 (9.4)
Blood creatinine increased 3 (3.6) 0 5 (5.9)
Renal impairment 0 1 (1.2) 2 (2.4)
Renal failure chronic 1 (1.2) 0 1 (1.2)
Renal failure 1 (1.2) 1 (1.2) 0
Renal failure acute 1 (1.2) 0 0
Hypotension/dehydration/hy-
povolemia
5 (6.0) 8 (9.6) 11 (12.9)
Fracture 0 5 (6.0) 8 (9.4)
Hypertension 6 (7.1) 3 (3.6) 5 (5.9)
Micturition urgency 0 (0) 5 (6.0) 2 (2.4)
Hyperkalemia 13 (15.5) 10 (12.0) 8 (9.4)
Events of hypoglycemia
Total patients with hypogly-
cemia
43 (51.2) 38 (45.8) 33 (38.8)
Major episode of hypoglyce-
mia a
4 (4.8) 0 2 (2.4)
Data are means±s.d. or n (%) and include data after rescue.
aMajor episode defined as a symptomatic episode requiring third-party assistance
owing to severe impairment in consciousness or behavior with a capillary or
plasma glucose value o54 mg/dl and prompt recovery after glucose or glucagon
administration.
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caloric balance, or this patient population may be more
susceptible to weight loss from glucosuria, requiring less
glucosuria to drive weight change. Hormones regulating
blood glucose (for example, glucagon, insulin, and cortisol)
are different from those regulating weight (for example,
ghrelin and leptin); therefore, one might expect to see
different boundaries for these two outcomes. Further
investigation is required to understand the dissociation of
glycemic efficacy from weight efficacy seen in this trial. The
FPG outcome points to the fact that there is still some
glycemic efficacy in this group, although this study is not
powered to empirically determine significance. The blood
pressure response, which is the cumulative effect of weight
loss, natriuresis, and osmotic diuresis, is not expected to be
directly dependent on glycemic control, although it is
partially dependent on weight change.
Adverse events were balanced among treatment and
placebo groups through 104 weeks, except the following:
(1) vulvovaginitis and balanitis, and (2) fractures. Genital
infection was more frequent with dapagliflozin than with
placebo, as has been seen in other studies.4–9 Urinary glucose
is thought to explain this increase in infections, serving
as a growth substrate for genital fungal pathogens. The
significance of the numeric increase in fractures observed
with dapagliflozin in this study is uncertain. Many of the
fractures were in places not suggestive of bone health issues
(for example, toes and patella). The dapagliflozin groups had
higher rates of neuropathy and orthostatic hypotension at
baseline, conceivably predisposing them to falls. Given the
small numbers, the increased fracture incidence could be a
chance phenomenon. No increase in fractures was observed
in pooled data from patients across the dapagliflozin clinical
studies with stage 3A CKD, or in patients with normal to
mildly impaired renal function.12,13 In addition, dapagliflozin
has been shown to have no effect on bone mineral density or
on markers of bone turnover in patients with normal to
mildly impaired renal function.14 Although there was no
assessment of biomarkers for bone metabolism conducted for
this study, the imbalance in fractures raises a safety question
specific to patients with advanced (stage 3B or greater) CKD
and calls for further study of the issue whether this
population is going to be treated with the drug.
Mean eGFR and creatinine clearance fell after 1 week of
dapagliflozin treatment, but stabilized thereafter through 104
weeks of therapy, whereas these parameters slowly declined in
the placebo group. The initial reduction in eGFR associated
with dapagliflozin may be related to a small antihypertensive
and diuretic effect, as well as increased tubuloglomerular
feedback.15 Importantly, the change in GFR from baseline at
week 104 was similar in the dapagliflozin and placebo groups.
Patients receiving dapagliflozin were more likely to regress to
a lower albumin excretion category than patients receiving
placebo. Thus, it will be of great interest to see whether
dapagliflozin reduces renal functional loss and worsening of
albuminuria.
Dapagliflozin was associated with fewer episodes of, and
fewer discontinuations for, hyperkalemia compared with
placebo. This protective effect is most likely due to osmotic
diuresis induced by dapagliflozin in patients with restricted
ability to excrete potassium.
The study has several limitations. The use of insulin-based
regimens in almost two-thirds of patients, often with sliding-
scale administration, made accurate capture of insulin dosing
difficult. Unmeasured differential behavior with respect to
sliding scale and other adjustments of insulin between
placebo and dapagliflozin could blunt the apparent efficacy
Table 6 | Summary of laboratory parameters at 104 weeks
Placebo
Dapagliflozin
5mg
Dapagliflozin
10mg
N 84 83 85
Serum creatinine (mg/dl)
Baseline 1.46 (0.35) 1.53 (0.33) 1.52 (0.32)
Change at 104
weeks
0.09 [0.039] 0.06 [0.043] 0.12 [0.044]
Urinary albumin:creatinine ratio (mg/g)
Baseline 478 (1193) 468 (851) 401 (785)
Change at 104
weeks
69.7 [80.1] 78.0 [112.5]  11.69 [148.6]
Urinary protein:creatinine ratio (mg/mg)
Baseline 0.75 (1.77) 0.72 (1.23) 0.63 (1.12)
Change at 104
weeks
0.09 [0.11] 0.17 [0.19]  0.03 [0.21]
Serum magnesium (mEq/l)
Baseline 1.72 (0.23) 1.67 (0.20) 1.70 (0.18)
Change at 104
weeks
 0.06 [0.026] 0.16 [0.034] 0.12 [0.031]
Serum calcium (mg/dl)
Baseline 9.55 (0.41) 9.50 (0.49) 9.52 (0.42)
Change at 104
weeks
 0.22 [0.080]  0.15 [0.089]  0.10 [0.067]
Serum phosphorus (mg/dl)
Baseline 3.84 (0.61) 3.65 (0.51) 3.67 (0.52)
Change at 104
weeks
 0.13 [0.109] 0.03 [0.076] 0.28 [0.075]
Parathyroid hormone (pg/ml)
Baseline 66.5 (53.0) 70.2 (57.4) 68.5 (48.9)
Change at 104
weeks
3.67 [10.31] 17.26 [8.84] 15.13 [6.22]
Serum uric acid (mg/dl)
Baseline 7.05 (1.94) 7.30 (2.12) 7.13 (1.71)
Change at 104
weeks
 0.16 [0.247]  0.67 [0.254]  0.39 [0.204]
Systolic blood pressure (mmHg)
Baseline 130.7 (14.1) 131.8 (17.9) 133.7 (17.0)
Change at 104
weeks
4.14 (14.07)  0.25 (18.30)  2.51 (16.33)
Diastolic blood pressure (mmHg)
Baseline 73.6 (9.29) 72.5 (9.45) 73.8 (9.30)
Change at 104
weeks
 0.48 (9.60)  0.55 (11.63)  1.27 (9.49)
Data are mean (s.d.) at baseline or mean change [s.e.], or (s.d.) for blood pressure,
from baseline and include data after rescue.
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of dapagliflozin. A second limitation is the relatively small
size of the study, which was powered for a 0.6% change in
HbA1c and therefore limited in its ability to demonstrate
smaller glycemic effects. Limited data regarding relevant
effect size were available at the time this trial was designed. As
we now know from the study of patients with relatively
normal kidney function,5 and the diminished pharmacody-
namic effect in patients with decreased renal function,16 this
study may be considered underpowered and subject to type
2 error. Finally, lack of racial diversity in this study could
potentially affect its generalizability.
Improvement of glycemic measures with dapagliflozin in
this population was not statistically significant because of the
inadequate renal function in these patients. The reduced
glucose excretion in this population still appears sufficient to
account for the weight loss and blood pressure reduction,
which are important therapeutic considerations in patients
with diabetes and CKD. Apart from the imbalance in
fracture, the safety profile of dapagliflozin was similar to
that observed in studies involving patients with T2DM and
normal renal function to mild renal impairment.
MATERIALS AND METHODS
Trial design
This multicenter, randomized, double-blind, placebo-controlled,
parallel-group, phase 2/3 study took place in 111 sites in United
States, Argentina, Canada, India, Mexico, Peru, Italy, Australia,
France, Spain, Denmark, Puerto Rico, and Singapore. Institutional
review boards or independent ethics committees approved this
protocol. This study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines. Each
patient provided written informed consent.
Male and female patients X18 years old with T2DM and
inadequate glycemic control defined as HbA1c X7.0 and p11.0%
were enrolled from 19 June 2008 to 21 May 2009. Patients had
eGFR values of 30 to 59ml/min per 1.73m2 and body mass
indexp45.0 kg/m2. Stable antidiabetic regimen was defined as diet
and exercise therapy alone or in combination with a regimen of any
approved antidiabetic medication(s), including insulin, in which
either doses of oral antidiabetic medications, exenatide, or pramlin-
tide had not changed during 6 weeks before enrollment, or doses of
long-acting insulin or intermediate-acting insulin had not varied by
420% during 6 weeks before enrollment. Exclusion criteria included
aspartate or alanine aminotransferases43.0 times the upper limit of
normal, serum total bilirubin 42.0mg/dl, history of diabetes
insipidus or diabetic ketoacidosis or hyperosmolar nonketotic coma,
uncontrolled hypertension defined as systolic blood pressure X180
mmHg and/or diastolic blood pressure X110mmHg, or specified
cardiovascular/vascular diseases within 6 months of enrollment visit.
Renal exclusion criteria included the need for hemodialysis or renal
replacement therapy, history of rapidly progressing renal disease,
lupus nephritis, renal or systemic vasculitis, renal artery stenosis,
renal transplant, or hepatic disease. Diabetic nephropathy and
hypertension were identified at the discretion of the treating
physician, as no strict definitions were provided.
A 7-day lead-in period included diet and exercise counseling,
which continued throughout the study. On day 1, patients were
randomized in a double-blind manner to either placebo, dapagli-
flozin 5-mg, or dapagliflozin 10-mg daily, in addition to their
original pre-enrollment antidiabetic regimen. Randomization was
stratified based on pre-enrollment antihyperglycemic therapy (strata
were: insulin-based regimen, sulfonylurea-based regimen, thiazoli-
dinedione-based regimen, or other regimen). During the first 24
weeks (short-term period), patients received rescue medication (any
approved antidiabetic agent except metformin) if FPG 4270mg/dl
(weeks 4–6), 4240mg/dl (weeks 6–12), or 4200mg/dl (weeks
12–24). Patients completing the first 24 weeks were eligible to
continue into an additional 28-week (long-term) period and were
eligible to receive rescue medication if HbA1c 48.0%. Patients
completing the first 52 weeks (the short-term plus long-term
periods) were eligible to continue into the extension period (an
additional 52 weeks) and received rescue medication if HbA1c
47.5% (weeks 52–76) and 47.0% (weeks 76–104).
Outcomes of interest
Efficacy analyses included or excluded data after glycemic rescue as
indicated. The primary efficacy objective compared the change from
baseline in HbA1c with each dose of dapagliflozin vs. placebo at
2.0
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Figure 3 |Mean change from baseline after adjustment for baseline value in eGFR for placebo (circles, solid line), dapagliflozin 5-mg
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Kidney International (2014) 85, 962–971 969
DE Kohan et al.: Renal impairment, diabetes, and dapagliflozin c l i n i ca l t r i a l
24 weeks. The secondary objectives compared the following: (1) change
from baseline in FPG and weight for each dose of dapagliflozin vs.
placebo at 24 weeks; and (2) change from baseline in eGFR
(Modification of Diet in Renal Disease Study equation (four-
variable)) and creatinine clearance (Cockcroft and Gault method)
for each dapagliflozin dose vs. placebo at 52 weeks.
All safety analyses included data after glycemic rescue. Safety
outcomes included serious and nonserious adverse events, dis-
continuations owing to adverse events, hypoglycemia, laboratory
abnormalities, electrocardiograms, and vital signs. Seated blood
pressure and heart rate determinations were made in triplicate at
each study visit, and supine and standing blood pressure measure-
ments were taken at baseline, and at weeks 1, 12, 24, 52, and 104.
Urinary albumin:creatinine ratio and urinary protein:creatinine
ratio were based on untimed spot urine sample collections. Patients
were actively monitored throughout the trial for clinical signs and
symptoms suggestive of urinary tract infection and genital infection,
with questioning by the investigator at every visit.
A central laboratory evaluated the assays for the efficacy and
safety outcomes, using high-performance liquid chromatography for
HbA1c and colorimetric indicator for plasma creatinine and urinary
albumin:creatinine ratio.
Statistical analysis
The primary efficacy analysis was based on an analysis of covariance
model with treatment group and pre-enrollment antihyperglycemic
therapy stratum as fixed effects and the baseline value as a covariate.
For patients with no week 24 measurement or rescue before week 24,
the last available post-baseline measurement (last observation carried
forward) before rescue and before week 24 was used.17 Treatment-by-
baseline interaction and treatment-by-stratification factor interaction
were tested at the 0.10 level of significance, and no significant
interaction was found. Several sensitivity analyses (completers,
longitudinal repeated-measure analysis with or without data after
rescue) were performed. Over 104 weeks, longitudinal repeated-
measure analysis was used to estimate the change in HbA1c, FPG,
and total body weight from baseline; the model included categorical
fixed effects of treatment, strata based on pre-enrollment antidiabetic
therapy category, week, and treatment-by-week interaction, as well as
continuous fixed covariates of baseline measurement and baseline
measurement-by-week interaction.
With 80 patients per treatment group, there was at least 88%
power to detect a difference of 0.6% in mean change from baseline
in HbA1c between each dapagliflozin treatment group and placebo
at a significance level of 0.027, using Dunnett’s adjustment and
assuming an s.d. of 1.1%. Assuming that 5% of the patients would
not have a post-baseline assessment, a total of 252 patients (84
patients per treatment group) needed to be randomized.
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